Cell and gene therapies present tremendous clinical and humanistic opportunity to change the course of disease but also present several unique aspects that differ from more traditional therapies. These differences will impact how innovators develop evidence and manufacture and distribute products. Payers also need to adapt how they assess value, make coverage decisions, and manage reimbursement.
This half-day course Overcoming Unique Challenges in Evidence Development and Assessment for Access and Reimbursement/Coverage of Cell and Gene Therapies will provide foundational information to equip the audience with how to best develop a compelling evidence package for cell and gene therapies, how payers will apply their assessment in decision-making, and how to best bridge the gap between these two. The program will be structured with a mixture of presentations and panel discussions.
At the completion of this program, participants should be able to:
- Understand the key components of the scientific underpinning of cell and gene therapy and future technologies.
- Understand nuances in develop value evidence for cell and gene therapies.
- Gain real customer insights. AMCP thought leaders and experts bring expertise into the evolving demands regarding payer evidence needs for cell and gene therapies.
Larry Blandford: Executive Vice President (Precision Value and Health)
- Stephen Majors: Director of Public Affairs (Alliance for Regenerative Medicine (ARM))
- Ramesh Arjunji, PhD: Vice President, Value and Access (AvroBio)
- Rocio Manghani, MPH: Senior Vice President, Market Access (Gamida Cell)
- Erik Schindler, PharmD, BCPS: Director, Emerging Therapeutics and Outcome-Based Contracting, (United Healthcare Pharmacy)
- Philip Cyr, MPH: Senior Vice President (Precision Value and Health)
- Erin Lopata, PharmD: MPH Vice President, Access Experience Team (PRECISIONvalue)